REFERENCES
- Allegra®, Zyrtec® and Claritin® in Physician's Desk Reference, 55th Edition, Medical Economics Company, Inc., Montvale, NJ (2001)
- Petition of Robert Seidman dated July 21, 1998 to Dockets Management Branch, Food and Drug Administration, http://www.fda.gov/ohrms/dockets/dockets/98p0610/cp00001.pdf
- Exemptions And Considerations For Certain Drugs, Devices, And Biological Products, Section 503(b)(1), Federal Food, Drug and Cosmetic Act,http://www.fda.gov/opacom/laws/fdcact/fdcact5a.htm
- Soller R.W. OTCness, Drug Inf. J. 1998; 32: 555–560
- Rx Antihistamine OTC availability Subject of May NDAC Meeting, F-D-C Reports-The Tan Sheet, 9 (12), 3 (2001)
- Briefing book provided by Schering Plough Corporation for the 11 May, 2001 Nonprescription Drugs Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3737b_15_schering-plough.html
- Submission of American Academy of Allergy, Asthma and Immunology (AAAAI) to FDA Docket # 98P-0610, http://www.fda.gov/ohrms/dockets/dockets/98p0610/98P-0610_emc-000005.doc
- Submission of American Academy of Otolaryngology–Head & Neck Surgery Inc. to FDA Docket # 98P-0610, http://www.fda.gov/ohrms/dockets/dockets/98p0610/98P-0610-c000005.PDF
- Federal Register 1992; 57, 58,355–,376, Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Drug Products for Over-the-Counter Human Use; Final Monograph for OTC Antihistamine Drug Products
- Draft Summary of Risk Issues related to Loratadine, Fexofenadine and Cetirizine prepared by CDER, FDA for the 11 May, 2001 Nonprescription Drugs Advisory Committee Meeting, http://www.fda.gov/ohrms/dockets/ac/01/briefing/3737b_03_risk.html
- Over-the-Counter Drug Products; Public Hearing, Federal Register, 65, 24,704–24,706 (2000)
- Metaproterenol Sulfate Metered Dose Inhaler Drugs For Use as a Bronchodilator; Marketing Status; Proposed Rule-Related Notice, Federal Register, 48, 24,925–24,928 (1983)